ABBV
AbbVie Inc.
NYSE: ABBV · North Chicago, IL · Healthcare
$225.42+2.35 (+1.05%)Closed
Market Cap$398.18B
Cash$9.39Bmost recent
Runwayprofitable
P/E (TTM)95.5EPS $2.36
52-Wk Range$176.56 – $238.71
Avg Volume6.2M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$225.42+41.5%
Pipeline

Drug candidates sponsored by AbbVie · ClinicalTrials.gov

77 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4lopinavir/ritonavir
Human Immunodeficiency Virus
Completed
2006-12past
1
Phase 4Adalimumab
Axial Spondyloarthritis+5 more
Completed
2018-05-21past
6
Phase 4AndroGel 1.62%
Hypogonadism
Completed
2021-12-07past
1
Phase 4BOTOX®/VISTABEL®
Facial Corrections+1 more
Completed
2023-10-05past
1
Phase 4Risankizumab
Moderate Plaque Psoriasis+2 more
Recruiting
2027-08
4
Phase 3ABT-712
Chronic Low Back Pain
Completed
2009-04past
2
Phase 3Fluvoxamine maleate
Obsessive Compulsive Disorder
Completed
2015-06-18past
1
Phase 3ombitasvir/paritaprevir/ritonavir
Chronic Hepatitis C+2 more
Completed
2016-08past
1
Phase 3ombitasvir/paritaprevir/ritonavir and dasabuvir
Chronic Hepatitis C Infection+1 more
Completed
2016-10-07past
3
Phase 2ABT-493
Chronic Hepatitis C+1 more
Completed
2016-10-25past
1
Phase 3ABT-493/ABT-530
Hepatitis C Virus Infection+4 more
Completed
2017-01-19past
2
Phase 3Palivizumab
Respiratory Syncytial Virus (RSV)
Completed
2017-07-13past
1
Phase 3Glecaprevir/Pibrentasvir
Hepatitis C Virus (HCV)
Completed
2018-11-15past
1
Phase 3Rovalpituzumab tesirine
Small Cell Lung Cancer
Completed
2020-02-12past
1
Phase 3Placebo
Rheumatoid Arthritis+3 more
Completed
2024-05-21past
5
Phase 3Atogepant 60 mg
Chronic Migraine+1 more
Completed
2024-06-11past
1
Phase 2Unnamed
Nasolabial Folds
Completed
2025-02-03past
1
Phase 3Tavapadon
Parkinson Disease
Completed
2025-12-01past
1
Phase 3Telisotuzumab adizutecan
Colorectal Cancer+1 more
Recruiting
2027-12
4
Phase 2ABT-089
Attention-Deficit/Hyperactivity Disorder
Completed
2008-08past
2
Phase 2ABT-869
Advanced Hepatocellular Carcinoma
Completed
2011-06past
1
Phase 2ABT-267
Chronic Hepatitis C Infection
Completed
2012-04past
1
Phase 2ABT-652 6 mg
Diabetic Neuropathic Pain
Terminated
2012-05past
1
Phase 2ABT-888
Ovarian Cancer
Completed
2013-06past
1
Phase 2ABT-126
Alzheimer's Disease
Completed
2013-10past
1
Phase 2Veliparib
Brain Metastases From Non-small Cell Lung Cancer+1 more
Completed
2015-01-22past
2
Phase 1ABT-263
Chronic Lymphoid Leukemia+6 more
Completed
2016-10past
2
Phase 2Risankizumab 600 mg IV
Crohn Disease
Completed
2019-06-19past
1
Phase 1Venetoclax
Acute Myelogenous Leukemia+1 more
Completed
2021-08-10past
1
Phase 1AGN-241622
Presbyopia
Terminated
2022-12-05past
1
Phase 2ABBV-154
Crohn's Disease
Terminated
2023-07-20past
1
Phase 2ABBV-4083
Onchocerciasis
Terminated
2023-08-29past
1
Phase 2CVL-865
Seizures
Terminated
2024-12-05past
1
Phase 2Linaclotide
Functional Constipation
Completed
2025-06-09past
1
Phase 2ABBV-706
Small Cell Lung Cancer
Recruiting
2029-05
2
Phase 2ABBV-142
Idiopathic Pulmonary Fibrosis
Recruiting
2029-09
1
Phase 1ABT-288
Schizophrenia
Completed
2009-12past
1
Phase 1navitoclax
Lymphoma, Including Chronic Lymphocytic Leukemia+1 more
Completed
2011-05past
1
Phase 1ABT-981
Osteoarthritis
Completed
2013-10past
1
Phase 1ABT-122
Rheumatoid Arthritis
Completed
2014-05past
1
Phase 1duvelisib
Lymphoma
Completed
2016-12past
1
Phase 1ABBV-8E12
Progressive Supranuclear Palsy (PSP)
Completed
2019-11-20past
1
Phase 1ABBV-321
Advanced Solid Tumors Cancer
Completed
2021-04-14past
1
Phase 1Unnamed
Atopic Dermatitis
Terminated
2022-01-31past
1
Phase 1Risankizumab Dose A
Healthy Volunteers
Completed
2023-04-20past
1
Phase 1Emraclidine
Hepatic Impairment
Completed
2025-02-21past
1
Phase 1ABBV-547
Healthy Volunteer
Recruiting
2027-09
1
N/AUnnamed
Rheumatoid Arthritis+4 more
Completed
2012-06past
1
N/AUnnamed
Rheumatoid Arthritis
Completed
2012-07past
1
N/AUnnamed
Ankylosing Spondylitis
Completed
2014-05past
1
N/AUnnamed
Crohn's Disease
Completed
2014-05past
1
N/AUnnamed
Rheumatoid Arthritis
Completed
2015-09past
1
N/AUnnamed
Human Immunodeficiency Virus
Completed
2016-01past
1
N/AUnnamed
Crohn's Disease
Completed
2016-02past
1
N/AUnnamed
Polyarticular Juvenile Idiopathic Arthritis
Completed
2016-04past
1
N/AUnnamed
Moderate to Severe Plaque Psoriasis
Completed
2016-05past
1
N/AUnnamed
Prostate Cancer
Completed
2016-09-08past
1
N/AUnnamed
Crohn's Disease+6 more
Completed
2019-02-28past
1
N/AUnnamed
Moderate to Severe Plaque Psoriasis
Completed
2019-06-30past
1
N/AUnnamed
Psoriasis
Completed
2019-08-06past
1
N/AUnnamed
Parkinson's Disease (PD)
Completed
2020-01-07past
1
N/AUnnamed
Polyarticular Juvenile Arthritis
Completed
2020-09-14past
1
N/AUnnamed
Hepatitis C Virus (HCV)
Completed
2020-09-15past
1
N/AUnnamed
Cancer+2 more
Completed
2022-10-21past
1
N/AUnnamed
Hepatitis C Virus (HCV)
Completed
2023-12-31past
1
N/AUnnamed
Endometriosis
Completed
2024-03-26past
1
N/AOptive MEGA-3 (OM3)
Dry Eye
Completed
2024-07-18past
1
N/AUnnamed
Rheumatoid Arthritis (RA)
Completed
2024-07-30past
1
N/ANext Generation Emulsion Preservative Free Eye Drops (NGE-UD)
Dry Eye
Completed
2024-10-14past
1
N/AUnnamed
Atopic Dermatitis
Completed
2024-11-02past
1
N/AUnnamed
Ulcerative Colitis
Completed
2025-12-09past
1
N/AUnnamed
Ankylosing Spondylitis
Completed
2025-12-11past
1
N/AUnnamed
Chronic Lymphocytic Leukemia
Active, not recruiting
2026-06-30
1
N/AUnnamed
Ulcerative Colitis
Recruiting
2028-07
1
N/AUnnamed
Crohn's Disease
Active, not recruiting
2028-07
1
N/AUnnamed
Migraine
Active, not recruiting
2029-02
1
N/AUnnamed
Migraine
Recruiting
2036-01
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for ABBV. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.